Palatin Technologies, Inc.
PTN
PTN: Palatin Technologies Inc is a part of the healthcare sector. The company is engaged in developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its main product in clinical development is bremelanotide, which treats hypoactive sexual desire disorder, which is a type of female sexual dysfunction.
moreShow PTN Financials
Recent trades of PTN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by PTN's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Followers on PTN's company Twitter account
Number of mentions of PTN in WallStreetBets Daily Discussion
Recent insights relating to PTN
Recent picks made for PTN stock on CNBC
ETFs with the largest estimated holdings in PTN
Flights by private jets registered to PTN